⚠️ Mechanism
Ginkgo is a moderate inhibitor of CYP2C19, which decreases metabolism of CYP2C19 substrates, potentially increasing their plasma concentrations and risk of adverse effects.
📋 Effect
Increased plasma levels of propranolol (beta-blockers), potentially leading to toxicity or enhanced adverse effects.
💊 Management
Monitor for increased adverse effects of propranolol. Dose reduction may be necessary. Consider alternative supplement or consult healthcare provider.
Plain Language Summary
This combination is moderately risky because Ginkgo can slow down how your body processes certain beta-blockers. This may cause the medication to build up in your system, which could increase the risk of side effects.
Source
Flockhart CYP450 Table (drug-interactions.medicine.iu.edu)
Supporting Research
Ginkgo biloba for cognitive impairment and dementia
Ginkgo biloba for cognitive impairment and dementia
Ginkgo biloba for tinnitus
Ginkgo biloba for tinnitus
Ginkgo biloba for intermittent claudication
The Comparative Efficacy of Multiple Interventions for Mild Cognitive Impairment in Alzheimer's Disease: A Bayesian Network Meta-Analysis
Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis
Ginkgo biloba for intermittent claudication
Medical Disclaimer: This interaction record is for informational and educational purposes only and does not constitute medical advice. Drug-supplement interactions can be dangerous. Always consult your healthcare provider or pharmacist before combining any supplement with prescription medications. Do not stop or change any medication without professional guidance.